A director at Greenyard NV bought 27,914,598 shares at 7.400EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
AB InBev: 2Q25 results. Air France-KLM: Nice beat, let's see how FY25 finishes. AMG: Uptrend continues in 2Q25 with 23% EBITDA beat and guidance up to +US$200m. Aperam: Slight 2Q25 EBITDA beat, 3Q25 seen down QoQ. Arcadis: EBITA margin held up well in 2Q25, order intake mixed. Ayvens: 2Q25 results. Azelis: Soft but largely in-line 2Q25 with EMEA offsetting weaker APAC. Bekaert: 1H25 miss and lowered outlook to result in c.5% consensus downside. Corbion: Taking it to the wire. dsm...
Since our last update, the market has experienced a wave of profit warnings and significant FX volatility. As a result, we find it necessary to revise our estimates. We are lowering our adjusted EBITA forecast from €471m to €451m, primarily due to adverse FX movements. Furthermore, we decrease our GPm expectations for the Americas. We anticipated that improvements in the F&F segment would support margin expansion in 2Q25, the combination of FX headwinds, macroeconomic uncertainty, and unfavourab...
We lower expectations ahead of Azelis' 2Q25 results, driven by the prevailing uncertainty regarding trade and tariffs, especially in North America, and adverse FX trends. Our BUY stands, on a revised target price of €22 (previously €25), given Azelis's compelling valuation discount of c.30% relative to IMCD for a broadly similar medium-term growth dynamic and margin profile.
Ahold Delhaize: 2Q25 pre-close call feedback. Azelis: Attractive acquisition in personal care Italy. Econocom: Two UK/Ireland AV acquisitions disclosed. Staffing: Better French volumes in May even with easier comps, June outlook sluggish. Staffing: Dutch figs Period 6 volume and revenues weaker on tougher comps. UCB: Trump threatens a 200% tariff on pharmaceutical products
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.